Industries > Pharma > Global Blood Cancer Market Forecast to 2028

Global Blood Cancer Market Forecast to 2028

Immunotherapy, Chemotherapy, Targeted Therapy

PUBLISHED: 11 April 2019
PAGES: 92
PRODUCT CODE: PHA0412
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0412 Categories: , Tags: , , , , ,

The global blood cancer market reached $24bn in 2018 and is estimated to grow at a CAGR of 6.4% in the first half of the forecast period. Chemotherapy held 44% of the market in 2018.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new report you will receive 61 charts – all unavailable elsewhere.

This report provides clear detailed insight into the global blood cancer market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Revenue and growth forecasts to 2028 for the blood cancer market

• Revenue and growth forecast to 2028 for the blood cancer market by type of therapy:
• Chemotherapy
• Targeted therapy
• Immunotherapy

• Revenue and growth forecast to 2028 for the blood cancer market by regional and national market:
• The US
• Japan
• Germany
• France
• The UK
• Spain
• Italy
• Brazil
• Russia
• India
• China

Global Blood Cancer Market Forecast to 2028

For each national market, the revenue forecast is also broken down by submarket.

• For each national market, this report provides incident cases projection from 2018 to 2028 for:
• Leukaemia
• Non-Hodgkin Lymphoma
• Hodgkin Lymphoma
• Multiple Myeloma

• Discussion and profiles of the leading players in the blood cancer market:
• Amgen
• AstraZeneca
• Bayer
• Bristol-Myers Squibb (BMS)
• Celgene
• Johnson & Johnson
• Novartis
• Pfizer
• Roche

• Discussion on drugs that are currently in the R&D pipeline for Leukaemia, Lymphoma and Multiple Myeloma.

• Analysis of what stimulates and restrains the global blood cancer market: Porter’s Five Forces Analysis, Trends, Drivers and Challenges

• Key Questions Answered by this Report:
• How is the Blood Cancer market evolving?
• What are the drivers and restraints for the growth of the Blood Cancer market?
• How will each Blood Cancer submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2028?
• What will be the main driver for the overall market to 2028?
• How will political and regulatory factors influence the regional markets and submarkets?
• Will leading national Blood Cancer markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2028 and which geographical region will lead the market in 2028?
• Who are the leading players and what are their prospects over the forecast period?

Visiongain’s study is intended for anyone requiring commercial analyses for the global blood cancer market. You find data, trends and predictions.

Buy our report today Global Blood Cancer Market Forecast to 2028: Immunotherapy, Chemotherapy, Targeted Therapy.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Blood Cancer Market Forecast to 2028


Download sample pages

Complete the form below to download your free sample pages for Global Blood Cancer Market Forecast to 2028


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category